Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development

Liver damage and fibrosis are precursors of hepatocellular carcinoma (HCC). In HCC patients, sorafenib—a multikinase inhibitor drug—has been reported to exert anti-fibrotic activity. However, incomplete inhibition of RAF activity by sorafenib may also induce paradoxical activation of the mitogen-act...

Full description

Saved in:
Bibliographic Details
Published in:Theranostics
Main Authors: Sung, Yun-Chieh, Liu, Ya-Chi, Chao, Po-Han, Chang, Chih-Chun, Jin, Pei-Ru, Lin, Ts-Ting, Lin, Ja-An, Cheng, Hui-Teng, Wang, Jane, Lai, Charles P., Chen, Ling-Hsuan, Wu, Anthony Y., Ho, Ting-Lun, Chiang, Tsaiyu, Gao, Dong-Yu, Duda, Dan G., Chen, Yunching
Format: Artigo
Language:Inglês
Published: Ivyspring International Publisher 2018
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5817100/
https://ncbi.nlm.nih.gov/pubmed/29463989
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.21168
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items